第三方病毒特异性T细胞长期控制异基因造血干细胞移植后复发或难治性病毒感染
一项前瞻性研究纳入30例异基因造血干细胞移植后持续或复发性CMV(28例)、EBV(1例)或腺病毒(1例)感染患者,接受部分HLA匹配的第三方体外扩增病毒特异性T细胞输注(共50次,中位移植后75天)。输注安全,12个月总缓解累积发生率为93%,多数患者病毒学控制持久,5例在末次输注后重新启用抗病毒治疗。
要点
- 第三方病毒特异性T细胞输注安全且耐受良好,12个月总缓解累积发生率为93%。
- 多数患者病毒学控制持久,仅5例在末次输注后重新启用抗病毒治疗。
- CMV特异性T细胞免疫显著升高,与CD8+终末效应细胞升高同步。
核心结论
- 第三方病毒特异性T细胞显示持久获益,病毒学控制与CD8+效应T细胞恢复相关,后者可能由VST输注促进。
研究设计与样本
- 前瞻性研究纳入30例异基因造血干细胞移植后持续或复发性病毒感染患者,其中CMV 28例、EBV 1例、腺病毒1例。
- 患者接受部分HLA匹配的第三方体外扩增VST输注,共50次,中位移植后75天(范围37至349天)。
- 监测安全性、病毒动力学和免疫恢复12个月。
主要发现
- 输注安全且耐受良好,2例发生急性移植物抗宿主病,VST与受者中位HLA匹配为6个抗原中2个。
- 12个月时总缓解累积发生率为93%。
- 多数患者病毒学控制持久,5例在末次输注后重新启用抗病毒治疗。
- CMV特异性T细胞免疫显著升高,与CD8+终末效应细胞升高同步。
- PD-1在第三方T细胞输注前CD8+淋巴细胞上表达升高,并在病毒控制时仍保持升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor-derived adoptive T-cell therapy is a safe and effective treatment of viral infection posttransplant, but it is limited by donor serostatus and availability and by its personalized nature. Off-the-shelf, third-party virus-specific T cells (VSTs) appear promising, but the long-term safety and durability of responses have yet to be established. We conducted a prospective study of 30 allogeneic hemopoietic stem cell transplant (HSCT) patients with persistent or recurrent cytomegalovirus (CMV) (n = 28), Epstein-Barr virus (n = 1), or adenovirus (n = 1) after standard therapy. Patients were treated with infusions of partially HLA-matched, third-party, ex vivo-expanded VSTs (total = 50 infusions) at a median of 75 days post-HSCT (range, 37 to 349 days). Safety, viral dynamics, and immune recovery were monitored for 12 months. Infusions were safe and well tolerated. Acute graft versus host disease occurred in 2 patients, despite a median HLA match between VSTs and the recipient of 2 of 6 antigens. At 12 months, the cumulative incidence of overall response was 93%. Virological control was durable in the majority of patients; the reintroduction of antiviral therapy after the final infusion occurred in 5 patients. CMV-specific T-cell immunity rose significantly and coincided with a rise in CD8+ terminal effector cells. PD-1 expression was elevated on CD8+ lymphocytes before the administration of third-party T cells and remained elevated at the time of viral control. Third-party VSTs show prolonged benefit, with virological control achieved in association with the recovery of CD8+ effector T cells possibly facilitated by VST infusion. This trial was registered at www.clinicaltrials.gov as #NCT02779439 and www.anzctr.org.au as #ACTRN12613000603718.
引用
- Withers B, Blyth E, Clancy LE, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017. PMID: 29296867. doi:10.1182/bloodadvances.2017010223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。